Eagle Pharmaceuticals. has filed a patent for a method of treating chronic lymphocytic leukemia using bendamustine formulations designed for small volume intravenous administration. The method allows for shorter administration time without the active ingredient coming out of solution. The treatment involves parenterally administering a liquid composition over a period of less than or equal to about 20 minutes, with a volume of about 325 mL or less. The composition includes bendamustine, sulfobutyl ether beta-cyclodextrin, and a parenterally acceptable diluent such as Water for Injection, 0.9% saline, 0.45% saline, or 2.5% dextrose/0.45% saline. GlobalData’s report on Eagle Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eagle Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Eagle Pharmaceuticals's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230285563A1) describes a method for treating chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma. The method involves parenterally administering a liquid composition containing bendamustine, sulfobutyl ether beta-cyclodextrin, and a parenterally acceptable diluent to the subject over a period of less than or equal to about 20 minutes. The volume of the liquid composition administered is about 325 mL or less.
The liquid composition in the method may contain bendamustine at concentrations ranging from about 0.05 to about 6 mg/ml or from about 0.05 to about 3.2 mg/ml. The subject is administered a bendamustine dosage amount ranging from about 25 mg/m2 to about 100 mg/m2, with a specific dosage amount of about 100 mg/m2 mentioned. The volume administered can vary, with options of 325 ml +/- 10%, 250 ml +/- 10%, 100 ml +/- 10%, or 50 ml +/- 10%. The liquid composition can be administered over a period of about 15 minutes or about 10 minutes.
For the treatment of chronic lymphocytic leukemia, the liquid composition is administered intravenously in a volume of about 50 mL in about 10 minutes or less on days 1 and 2 of a 28-day cycle. The method can be repeated for up to 6 cycles.
For the treatment of indolent B cell non-Hodgkin's lymphoma, the liquid composition is administered intravenously in a volume of about 50 mL in about 10 minutes or less on days 1 and 2 of a 21-day cycle. The method can be repeated for up to 8 cycles.
This patent filing presents a method for treating chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma using a specific liquid composition containing bendamustine. The method involves parenteral administration of the composition over a short period of time, with specific dosage amounts and volumes mentioned. The method offers potential benefits in terms of convenience and efficiency in the treatment of these diseases.
To know more about GlobalData’s detailed insights on Eagle Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
